



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number : **0 549 318 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **92311681.8**

(22) Date of filing : **22.12.92**

(51) Int. Cl.⁵ : **C07C 401/00, C07J 9/00,
C07J 51/00, A61K 31/575,
A61K 31/59**

(30) Priority : **26.12.91 US 813852**

(43) Date of publication of application :
30.06.93 Bulletin 93/26

(84) Designated Contracting States :
AT BE CH DE DK ES FR IT LI NL SE

(71) Applicant : **WISCONSIN ALUMNI RESEARCH
FOUNDATION
614 North Walnut Street Post Office Box 7365
Madison Wisconsin 53707-7365 (US)**

(72) Inventor : **DeLuca, Hector Floyd
1809 Highway BB
Deerfield, Wisconsin 53531 (US)
Inventor : Nakagawa, Naoshi
4715 Sheboygan Avenue No.223
Madison, Wisconsin 53705 (US)**

(74) Representative : **Ellis-Jones, Patrick George
Armine
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5LX (GB)**

(54) **26,27-Dimethylene-1 alpha, 25-dihydroxyvitamin D₂ and 26,27-dihydroxyvitamin D₂ and methods for preparing same.**

(57) Vitamin D₂ analogs in which a cyclopentane ring is introduced onto the 25-carbon of the side chain of 1 α ,25-dihydroxyvitamin D₂ and its 24-epimer are described. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity than 1 α ,25-dihydroxyvitamin D₃ in their ability to mobilize calcium from bone. Because of their preferential calcemic activity, these compounds find utility in the treatment of diseases where bone formation is desired, such as osteoporosis.

EP 0 549 318 A2


Background of the Invention

With the discovery of 1 α ,25-dihydroxyvitamin D₃ as the active form of the vitamin has come an intense investigation of analogs of this hormonal form of vitamin D with the intent of finding analogs that have selective activity. By now, several compounds have been discovered which carry out the differentiative role of 1,25-dihydroxyvitamin D₃ while having little or no calcium activity. Additionally, other compounds have been found that have minimal activities in the mobilization of calcium from bone while having significant activities in stimulating intestinal calcium transport. Modification of the vitamin D side chain by lengthening it at the 24-carbon has resulted in loss of calcium activity and either an enhancement or undisturbed differentiative activity. Placing the 24-methyl of 1 α ,25-dihydroxyvitamin D₂ in the epi-configuration appears to diminish activity in the mobilization of calcium from bone. On the other hand, increased hydrophobicity on the 26 and 27-carbons seems to increase the total activity of the vitamin D compounds provided the 25-hydroxyl is present.

Summary of the Invention


The present invention provides novel compounds exhibiting a desired, and highly advantageous, pattern of biological activity. These compounds are characterized by a marked intestinal calcium transport activity, as compared to that of 1 α , 25-dihydroxyvitamin D₃, while exhibiting much lower activity than 1 α ,25-dihydroxyvitamin D₃ in their ability to mobilize calcium from bone. Hence, these compounds are highly specific in their calcemic activity. Their preferential activity on intestinal calcium transport and reduced calcium mobilizing activity in bone allows the in vivo administration of these compounds for the treatment of metabolic bone diseases where bone loss is a major concern. Because of their preferential calcemic activity, these compounds would be preferred therapeutic agents for the treatment of diseases where bone formation is desired, such as osteoporosis, osteomalacia and renal osteodystrophy.

Structurally, the key feature of the compounds having these desirable biological attributes is that they are analogs of 1,25-dihydroxyvitamin D₂ in which a cyclopentane ring is introduced onto the 25 carbon of the side chain of 1 α ,25-dihydroxyvitamin D₂ and its 24-epimer. Thus, the compounds of this type are characterized by the following general structure:



where R¹ and R² may be hydrogen or methyl with the proviso that when R¹ is hydrogen R² cannot be hydrogen and when R¹ is methyl R² cannot be methyl. The present invention, therefore, provides novel compounds showing preferential activity on intestinal calcium transport and reduced calcium mobilizing activity in bone, and are useful for the treatment of metabolic bone disease, such as osteoporosis, where bone loss is a major concern. More specifically, the compounds are 26,27-dimethylene-1 α ,25-dihydroxyvitamin D₂ and 26,27-dimethylene-24-epi-1 α ,25-dihydroxyvitamin D₂.

This invention also provides novel intermediate compounds formed during the synthesis of the end products. Structurally, the intermediate compounds are characterized by the following general structure:



where R^1 and R^2 may be hydrogen or methyl with the proviso that when R^1 is hydrogen R^2 cannot be hydrogen and when R^1 is methyl R^2 cannot be methyl, and R^3 , R^4 and R^5 may be hydrogen or a hydroxyprotecting group.

Brief Description of the Drawings

Fig. 1 is a graph illustrating the percent HL-60 cell differentiation as a function of the concentration of 26,27-dimethylene-1 α ,25-dihydroxyvitamin D₂, its 24-epimer and 1 α ,25-dihydroxyvitamin D₃; and Fig. 2 is a graph illustrating the relative activity of 26,27-dimethylene-1 α ,25-dihydroxyvitamin D₂, its 24-epimer and 1 α ,25-dihydroxyvitamin D₃ in binding to the 1,25-dihydroxyvitamin D pig intestinal nuclear receptor.

Detailed Description of the Invention

As used in the description and in the claims, the term hydroxy-protecting group signifies any group commonly used for the temporary protection of hydroxy functions, such as for example, alkoxy carbonyl, acyl, alkylsilyl, and alkoxyalkyl groups, and a protected hydroxy group is a hydroxy function derivatized by such a protecting group. Alkoxy carbonyl protecting groups are groupings such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl. The term 'acyl' signifies an alkanoyl group of 1 to 6 carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6 carbons, such as an oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such as benzoyl, or a halo, nitro or alkyl substituted benzoyl group. The word 'alkyl' as used in the description or the claims, denotes a straight-chain or branched alkyl radical of 1 to 10 carbons, in all its isomeric forms. Alkoxyalkyl protecting groups are groupings such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl. Preferred alkylsilyl-protecting groups are trimethylsilyl, triethylsilyl, t-butyl dimethylsilyl, and analogous alkylated silyl radicals.

The present invention is more specifically described by the following examples, which are meant to be illustrative only of the process of synthesis and of the novel compounds, both end products and intermediates, obtainable thereby. In these examples, specific compounds identified by Arabic numerals (e.g. compounds 1, 2, 3, ... etc.) refer to the structures so numbered in the process schematics. Additionally examples are provided which are illustrative of the distinctive biological characteristics of the new compounds, such characteristics serving as a basis for the application of these compounds in the treatment of metabolic bone disease.

Preparation of Compounds General Procedures

Ultraviolet (UV) absorption spectra were recorded with a Perkin-Elmer Lambda 3b UV-VIS spectrophotometer. Nuclear magnetic resonance (NMR) spectra were recorded at 500 or 400 MHz with Bruker AM-500 multinuclear or AM-400 wide bore multinuclear spectrometers in the solvents noted. Chemical shifts (δ) are reported downfield from internal Me₄Si (δ 0.00) or CHCl₃ (δ 7.24). Low- and high-resolution mass spectra were recorded at 70 eV (unless otherwise stated) on a Kratos MS-50 TC instrument equipped with a Kratos DS-55 Data System. High resolution data were obtained by peak matching. Samples were introduced into the ion source maintained at 120-250°C via a direct-insertion probe. Silica gel 60 (Merck, 230-400 mesh) was used for column chromatography. High performance liquid chromatography (HPLC) was performed using a Waters Associates Liquid chromatograph equipped with a model 6000A solvent delivery system, a Model U6K Universal injector and a model 450 variable wavelength detector. Zorbax Sil Dupont column (4 x 6 mm x 25 cm)

was used. Solvent system: 15% 2-propanol in n-hexane. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl. Other solvents were purified by standard methods. Reactions involving vitamin D compounds were carried out under a nitrogen atmosphere with magnetic stirring.

5 Example 1 - Synthesis of 26,27-Dimethylene-1 α ,25-Dihydroxyvitamin D₂ (compound 11a) and its 24-epimer (compound 11b) (Process Schemes I and II)

In the synthesis described herein and in Schemes I and II, the following abbreviations are employed:

DHP:	2,3-dihydropyran
10 PPTS:	pyridinium p-toluenesulfonate
THP:	2-tetrahydropyranyl
THF:	tetrahydrofuran
Ts:	p-toluenesulfonyl
DMAP:	4-dimethylaminopyridine
15 DMF:	N,N-dimethylformamide
Ph:	phenyl
mCPBA:	m-chloroperbenzoic acid
TES:	triethylsilyl
TBAF:	tetrabutylammonium fluoride

20 The synthesis of compounds 11a and 11b may be summarized as follows:

The synthesis of side chain sulfones 7a,b, started from (R)- or (S)- methyl 3-hydroxy-2-methylpropanoate. The hydroxy group was protected to provide 2-tetrahydropyranyl (THP) ester 1. The ester 1 was converted into cyclopentanol 2 by an action of 1,4-dibromomagnesiobutane. The THP protecting group was removed to give diol 3. The primary hydroxy group of the diol was converted to the corresponding p-toluenesulfonate 4. The p-toluenesulfonate 4 was converted into phenylsulfide 5 on treatment with thiophenol. The sulfide was oxidized with peracid to sulfone 6. The tertiary hydroxy group was protected as triethylsilyl (TES) ether to give protected sulfone 7.

The sulfone 7 was condensed with aldehyde 9, after deprotonation with lithium diethylamide. The resulting hydroxy sulfone was acetylated, and then submitted to reductive elimination by sodium-amalgam to give (E)-olefin 8. The protective groups of 25- and 3 β -hydroxy groups were removed to give provitamin 10. Photo- and thermoisomerization of provitamin 10, followed by deprotection of the 1 α -hydroxy group yielded Vitamin D derivative 11.

30 It should be noted that in the present description and in scheme II, compound 9 is a known compound. Compound 9 may be prepared in accordance with PCT Patent Application No. WO88/07545.

35 (R)-Methyl 3-(2-tetrahydropyranyl)oxy-2-methylpropanoate 1a.

To a mixture of (R)-(-)-methyl 3-hydroxy-2-methylpropanoate (Aldrich; 4.94g, 41.8mmol) and 2,3-dihydropyran (4.22g, 50.2mmol) in dichloromethane (100mL) was added pyridinium p-toluenesulfonate (525mg, 2.08mmol) in one portion, and the mixture was stirred at ambient temperature for 2.25hr. To the mixture 2,3-dihydropyran (1.05g, 12.5mmol) was added and the mixture was stirred at ambient temperature for 30min. The mixture was poured into brine, and the organic layer was separated. The aqueous layer was extracted with diethyl ether, and the combined organic solutions were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 14.83g of an oily material, which was purified by column chromatography (silica gel 75g, ethyl acetate in n-hexane, 5-10%) to give 8.20g (97.0%) of 1a, as a colorless oil.

¹H-NMR δ (CDCl₃, 500MHz): 1.12, 1.13 (3H, two d, J=7.0Hz), 1.38-1.85 (6H), 2.21 (1H, m), 3.32-3.91 (4H), 3.63 (3H, br s), 4.54 (1H, dd, J=12.0 and 2.9Hz)

50 (S)-Methyl 3-(2-tetrahydropyranyl)oxy-2-methylpropanoate 1b.

In the same manner as for 1a, (S)-(-)-methyl 3-hydroxy-2-methylpropanoate (Aldrich; 4.96g, 42.0mmol) was converted into 8.38g (98.7%) of 1b, as a colorless oil, which showed virtually the same ¹H-NMR spectrum as 1a.

55 (R)-1-[1(2-Tetrahydropyranyl)oxy-2-propyl]-1-cyclopentanol 2a.

To an ice-cooled and stirred solution of 1,4-bisbromomagnesiobutane (prepared from 1.24g of magnesium turnings and 5.03g of 1,4-dibromobutane in 55mL of tetrahydrofuran) was added a solution of 1a (4.0g,

19.8mmol) in diethyl ether (30mL) dropwise at 0-25°C under nitrogen over 70min. The mixture was stirred at ambient temperature for 2hr, and then quenched by the addition of ammonium chloride solution. The organic layer was separated, and the aqueous layer was extracted with diethyl ether. The combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 5.98g of an oily material, which was purified by column chromatography (silica gel 60g, ethyl acetate in n-hexane, 2.5-20%) to give 3.58g (79.3%) of 2a, as a colorless oil.

¹H-NMR δ (CDCl₃, 500MHz); 1.00, 1.02 (3H, two d, J=7.3Hz), 1.38-1.93 (15H), 3.04 (1H, d, J=16.2Hz), 3.35 (0.5H, dd, J=9.8 and 4.9Hz), 3.42-3.56 (1.5H), 3.73-3.85 (1.5H), 3.97 (0.5H, dd, J=9.6 and 4.7Hz), 4.55 (1H, d, J=14.9Hz)

(S)-1-[1-(2-Tetrahydropyranyl)oxy-2-propyl]-1-cyclopentanol 2b.

In the same manner as for 2a, 1b (3.0g, 14.8mmol) was converted into 3.58g (quantitative) of 2b, as a colorless oil, which showed virtually the same ¹H-NMR spectrum as 2a.

(R)-1-(1-Hydroxy-2-propyl)-1-cyclopentanol 3a.

A mixture of 2a (3.42g, 15.0mmol) and pyridinium p-toluenesulfonate (188mg) in ethanol (100mL) was heated at 40-50°C with stirring for 10 hr. The mixture was diluted with toluene and a small amount of triethylamine was added to the mixture. After evaporation of ethanol, the residue was poured into brine and extracted with ethyl acetate until none of the product remained in the aqueous layer. The combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 2.53g of an oily material, which was purified by column chromatography (silica gel 20g, ethyl acetate in n-hexane, 20-50%) to give 1.88g (86.9%) of 3a, as a colorless oil.

¹H-NMR δ (CDCl₃, 500MHz); 0.97 (3H, d, J=7.2Hz), 1.38-1.86 (9H), 3.44 (1H, br s), 3.60 (1H, dd, J=9.7 and 4.8Hz), 3.81 (1H, d, J=8.0Hz), 3.93 (1H, br s)

(S)-1-(1-Hydroxy-2-propyl)-1-cyclopentanol 3b.

In the same manner as for 3a, 2b (3.41g, 14.9mmol) was converted into 1.98g (92.1%) of 3b, as a colorless oil, which showed the same ¹H-NMR spectrum as 3a.

(R)-1-(1-p-Toluenesulfonyloxy-2-propyl)-1-cyclopentanol 4a.

A mixture of 3a (1.79g, 12.4mmol), pyridine (5mL), and p-toluenesulfonyl chloride (4.26g, 22.3mmol) in dichloromethane (40mL) was stirred below 10°C for 2 days. The reaction mixture was poured into copper (II) sulfate solution and extracted with diethyl ether. The combined organic layers were washed with copper (II) sulfate solution, water, sodium bicarbonate solution and brine, and dried over sodium sulfate. Filtration and concentration gave 6.27g of an oily material, which was purified by column chromatography (silica gel 60g, ethyl acetate in n-hexane, 5-33%) to give 3.74g (quantitative) of 4a as a colorless oil.

¹H-NMR δ (CDCl₃, 500MHz); 0.95 (3H, d, J=6.8Hz), 1.28-1.92 (9H), 2.42 (3H, s), 3.91 (1H, dd, J=9.6 and 7.8Hz), 4.18 (1H, dd, J=9.6 and 4.6Hz), 7.32 (2H, d, J=8.0Hz), 7.75 (2H, d, J=8.0Hz)

(S)-1-(1-p-Toluenesulfonyloxy-2-propyl)-1-cyclopentanol 4b.

In the same manner as for 4a, 3b (1.92g, 13.3mmol) was converted into 3.46g (87.2%) of 4b, as a colorless oil, which showed the same ¹H-NMR spectrum as 4a.

(S)-1-(1-Benzenesulfonyl-2-propyl)-1-cyclopentanol 5a.

To a mixture of 4a (3.65g, 11.9mmol) and triethylamine (2.5mL) in N,N-dimethylformamide (18mL) was added thiophenol (1.8mL) in one portion. The mixture was stirred at ambient temperature overnight. The mixture was poured into water, and extracted with diethyl ether. The combined organic layers were washed with sodium bicarbonate solution and brine, and dried over sodium sulfate. Filtration and concentration gave 3.26g of an oily material, which was purified by column chromatography (silica gel 40g, ethyl acetate in n-hexane, 2.5-20%) to give 2.06g (73.3%) of 5a, as a pale yellow oil.

¹H-NMR δ (CDCl₃, 500MHz); 1.24 (3H, d, J=6.3Hz), 1.53 (1H, br s), 1.56-2.04 (9H), 2.85 (1H, dd, J=12.9 and 10.2Hz), 3.44 (1H, dd, J=12.9 and 2.8Hz), 7.28 (1H, t, J=8.0Hz), 7.39 (2H, t, J=8.0Hz), 7.46 (2H, d, J=8.0Hz)

(R)-1-(1-Benzenesulfonyl-2-propyl)-1-cyclopentanol 5b.

In the same manner as for 5a, 4b (3.65g, 11.9mmol) was converted into 2.23g (82.8%) of 5b, as a pale yellow oil, which showed the same ¹H-NMR spectrum as 5a.

(S)-1-(1-Benzenesulfonyl-2-propyl)-1-cyclopentanol 6a.

To a stirred and ice-cooled mixture of 5a (2.06g, 8.71mmol) in dichloromethane (19mL) and saturated sodium bicarbonate solution (28mL) was added m-chloroperbenzoic acid (85%, 4.24g, 20.9mmol) portionwise. The mixture was stirred in an ice bath for 50min. An excess amount of peracid was decomposed with sodium thiosulfate solution in the presence of a small amount of potassium iodide. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate solution and brine, and dried over sodium sulfate. Filtration and concentration gave 3.16g of an oily material, which was purified by column chromatography (silica gel 32g, ethyl acetate in n-hexane, 20-33%) to give 2.43g (quantitative) of 6a, as a colorless oil.

¹H-NMR δ (CDCl₃, 400MHz); 1.17 (3H, d, J=6.8Hz), 1.46-1.86 (8H), 2.18 (1H, m), 3.00 (1H, dd, J=14.5 and 9.0Hz), 3.41 (1H, br d, J=14.5Hz), 7.57 (2H, t, J=7.3Hz), 7.65 (1H, t, J=7.3Hz), 7.92 (2H, d, J=7.3Hz)

(R)-1-(1-Benzenesulfonyl-2-propyl)-1-cyclopentanol 6b.

In the same manner as for 6a, 5b (2.23g, 9.43mmol) was converted into 2.34g (92.5%) of 6b, as a colorless oil, which showed the same ¹H-NMR spectrum as 6a.

(S)-1-(1-Benzenesulfonyl-2-propyl)-1-triethylsiloxycyclopentane 7a.

To a solution of 6a (2.40g, 8.94mmol) and imidazole (1.22g, 17.9mmol) in N,N-dimethylformamide (20mL) was added chlorotriethylsilane (2.2mL, 13.1mmol) in one portion. The mixture was stirred at ambient temperature for 3d. The mixture was poured into ice water, and extracted with diethyl ether. The combined organic layers were washed with water and brine, and dried over sodium sulfate. Filtration and concentration gave 4.24g of an oily material, which was purified by column chromatography (silica gel 40g, ethyl acetate in n-hexane, 10%) to give 3.67g (quantitative) of 7a, as a colorless oil.

¹H-NMR δ (CDCl₃, 500MHz); 0.52 (6H, q, J=7.9Hz), 0.88 (9H, t, J=7.9Hz), 1.11 (3H, d, J=6.7Hz), 1.35-1.74 (8H), 2.06 (1H, m), 2.90 (1H, dd, J=14.4 and 9.7Hz), 3.42 (1H, d, J=14.4Hz), 7.56 (2H, t, J=7.5Hz), 7.64 (1H, t, J=7.5Hz), 7.91 (2H, d, J=7.5Hz)

(R)-1-(1-Benzenesulfonyl-2-propyl)-1-triethylsiloxycyclopentane 7b.

In the same manner as for 7a, 6b (2.20g, 8.19mmol) was converted into 3.19g (quantitative) of 7b, as a colorless oil, which showed the same ¹H-NMR spectrum as 7a.

(22E,24R)-26,27-Dimethylene-1 α , 3 β -bis(methoxycarbonyloxy)-25-triethylsiloxycyclopentane-5,7,22-triene 8a.

To a stirred solution of 7a (1.0g, 2.61mmol) in tetrahydrofuran (30mL) was added a solution of lithium diethylamide (prepared from 0.44mL of diethylamine and 2.5mL of 1.6N n-butyllithium in 7mL of tetrahydrofuran; 6.6mL) dropwise at -50-60°C under nitrogen. The mixture was stirred at -50-60°C for 1hr, and then cooled to -78°C. To the mixture was added a solution of (20S)-1 α , 3 β -bis(methoxycarbonyloxy)-20-methylpregna-5,7-dien-21-al 9 (670mg, 1.45mmol) in tetrahydrofuran (20mL) dropwise over a period of 50min. The mixture was stirred for 50min, and then quenched by the addition of saturated ammonium chloride solution and ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 2.97g of a residue. The residue was dissolved in dichloromethane (20mL) and to the solution was added 4-dimethylaminopyridine (2.12g, 17.4mmol) and acetic anhydride (1.3mL, 13.8mmol), and the mixture was stirred at ambient temperature overnight. The mixture was poured into a mixture of ice and ethyl acetate, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with brine and dried over sodium sulfate. Filtration and concentration gave 2.37g of a residue. The residue was dissolved in a mixture of tetrahydrofuran (30mL) and methanol (30mL) and the solution was stirred at -40 to -30°C. To the solution was added sodium bicarbonate (2.27g) and 5% sodium amalgam (pulverized and washed with tetrahydrofuran; 10.72g). The mixture was stirred at -40 to -30°C for 2.5hr. The super-

natant was filtered through a pad of Celite and the solids was washed with ethyl acetate. The combined organic solution was poured into a cold mixture of diluted hydrochloric acid and ethyl acetate, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 2.75g of a residue, which was purified by column chromatography (silica gel 50g, ethyl acetate in n-hexane, 5-50%) to give 648mg (65.2% from 9) of 8a, as white solids.

¹H-NMR δ (CDCl₃, 500MHz); 3.77 (3H, s), 3.78 (3H, s), 4.84 (1H, br s), 4.89 (1H, m), 5.20 (1H, dd, J=15.2 and 8.5Hz), 5.30 (1H, dd, J=15.2 and 8.6Hz), 5.36 (1H, m), 5.67 (1H, m)

(22E,24S)-26,27-Dimethylene-1 α ,3 β -bis(methoxycarbonyloxy)-25-triethylsiloxyergosta-5,7,22-triene 8b.

In the same manner as for 8a, 7b (1.0g, 2.61mmol) was converted into 803mg (67.4% from 9) of 8b, as white solids.

¹H-NMR δ (CDCl₃, 500MHz); 3.77 (3H, s), 3.79 (3H, s), 4.84 (1H, br s), 4.90 (1H, m), 5.21 (1H, dd, J=15.3 and 8.3Hz), 5.30 (1H, dd, J=15.3 and 8.4Hz), 5.37 (1H, m), 5.68 (1H, m)

(22E,24R)-26,27-Dimethylene-1 α -methoxycarbonyloxyergosta-5,7,22-triene-3 β ,25-diol 10a.

To a solution of 8a (597mg, 0.871mmol) in tetrahydrofuran (12mL) was added 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (4.4mL), and the mixture was stirred at ambient temperature overnight. The mixture was poured into cold brine, and extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate solution and brine, and dried over sodium sulfate. Filtration and evaporation gave 0.78g of a residue. To the residue was added methanol (50mL) and potassium carbonate (0.5g) and the mixture was stirred in a cold room (at 8°C) overnight. The mixture was poured into cold brine and extracted with ethyl acetate.

The combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration gave 1.54g of a residue, which was purified by column chromatography (silica gel 30g, ethyl acetate in n-hexane, 20-80%) to give 313mg (70.1%) of 10a, as white solids.

¹H-NMR δ (CDCl₃, 500MHz); 0.62 (3H, s), 1.00 (3H, s), 1.02 (3H, d, J=6.7Hz), 1.03 (3H, d, J=6.2Hz), 3.78 (3H, s), 3.99 (1H, br), 4.82 (1H, br s), 5.33 (2H, m), 5.36 (1H, m), 5.66 (1H, m)

(22E,24S)-26,27-Dimethylene-1 α methoxycarbonyloxyergosta-5,7,22-triene-3 β ,25-diol 10b.

In the same manner as for 10a, 8b (588mg, 0.858mmol) was converted into 302mg (68.7%) of 10b, as white solids.

¹H-NMR δ (CDCl₃, 500MHz); 0.63 (3H, s), 1.01 (3H, s), 1.03 (3H, d, J=6.8Hz), 1.04 (3H, d, J=6.5Hz), 3.78 (3H, s), 4.00 (1H, m), 4.82 (1H, br s), 5.34 (1H, dd, J=15.4 and 8.2Hz), 5.37 (1H, m), 5.40 (1H, dd, J=15.4 and 7.4Hz), 5.67 (1H, m)

(5Z,7E,22E,24R)-26,27-Dimethylene-9,10-secoergosta-5,7,10(19),22-tetraene-1 α ,3 β ,25-triol 11a.

A stirred and ice-cooled solution of 10a (103mg, 0.201mmol) in a mixture of diethyl ether (100mL) and benzene (20mL) was irradiated with medium pressure mercury lamp for 30min under nitrogen. The mixture was concentrated under reduced pressure and the residue was dissolved in benzene (20mL) and left to stand at ambient temperature for 15d under nitrogen covered with aluminum foil. The mixture was concentrated under reduced pressure, and the residue was treated with 1% lithium hydroxide hydrate solution in methanol (5mL) at ambient temperature for 1hr under nitrogen. The mixture was poured into ice water, and extracted with ethyl acetate. The combined organic layers were washed with brine, and dried over sodium sulfate. Filtration and concentration under reduced pressure gave an oily material, which was purified by column chromatography (silica gel 10g, ethyl acetate in n-hexane, 33-80%) to give 37.6mg (36.5%) of 10a and 27.4mg (30.0%, 47.2% based on recovery of 10a) of 11a, as white solids.

UV (ethanol); λ max 266nm, λ min 228nm MS (EI) m/z 454 (M⁺), 436 (M⁺-H₂O), 418 (M⁺-2H₂O), 400 (M⁺-3H₂O), 370 (M⁺+1-C₅H₉O), 352 (M⁺+1-C₅H₉O-H₂O), 334 (M⁺+1-C₅H₉O-2H₂O), 285 (M⁺+1-C₉H₁₂O₂-H₂O), 269 (M⁺-C₁₁H₁₉O-H₂O), 152 (C₉H₁₂O₂), 85 (base peak, C₅H₉O) HRMS m/z; Found 454.3434, Calcd. for C₃₀H₄₆O₃ 454.3447

¹H-NMR δ (CDCl₃, 500MHz); 0.55 (3H, s), 1.01 (3H, d, J=6.9Hz), 1.02 (3H, d, J=6.4Hz), 4.23 (1H, br s), 4.43 (1H, m), 4.99 (1H, s), 5.36-5.42 (3H), 6.01 (1H, d, J=11.3Hz), 6.38 (1H, d, J=11.3Hz)

HPLC T_R (min); 12.0

(5Z,7E,22E,24S)-26,27-Dimethylene-9,10-secoergosta-5, 7,10(19),22tetraene-1 α ,3 β ,25-triol 11b.

In the same manner as for 11a 10b, (100mg, 0.195mmol) was converted into 23.5mg (26.5%, 55.4% based on recovery of 10b) of 11b, as white solids, and 52.2mg (52.2%) of 10b, was recovered.

U V (ethanol); λ_{max} 266nm, λ_{min} 228nm MS (EI) m/z: 454 (M^+), 436 ($M^+ - H_2O$), 418 ($M^+ - 2H_2O$), 352 ($M^+ - I - C_5H_2O - H_2O$), 334 ($M^+ - I - C_5H_9O - 2H_2O$), 285 ($M^+ - I - C_9H_{12}O_2 - H_2O$), 269 ($M^+ - C_{11}H_{19}O - H_2O$), 152 ($C_9H_{12}O_2$), 85 (base peak, C_5H_9O)

HRMS m/z; Found 454.3472, Calcd. for $C_{30}H_{46}O_3$ 454.3447

1H -NMR δ ($CDCl_3$, 500MHz); 0.56 (3H, s), 1.03 (6H, d, J=7.0Hz), 4.23 (1H, br s), 4.43 (1H, m), 5.00 (1H, s), 5.32 (1H, s), 5.35 (1H, dd, J=15.4 and 7.6Hz), 5.38 (1H, dd, J=15.4 and 6.8Hz), 6.01 (1H, d, J=11.3Hz), 6.38 (1H, d, J=11.3Hz)

HPLC T_R (min); 12.1

Biological Activity of 26,27-Dimethylene-1 α ,25-Dihydroxyvitamin D₂ (Compound 11b) and its 24-epimer (compound 11a).Example 2 - Calcemic Activity

Weanling male rats obtained from the Holtzman Company were fed a low calcium (0.02%), 0.3% phosphorus, vitamin D-deficient diet for three weeks. After this time, the animals were severely hypocalcemic. They were then implanted with Alzet minipumps that delivered approximately 13 μ L of solution per day which contained the indicated dose in Table 1 dissolved in 5% ethanol, 95% propylene glycol. After 7 days the rats were killed and the duodena were used for determination of intestinal calcium transport by the everted intestinal sac technique (Martin & DeLuca, 1967) and serum calcium (bone calcium mobilization). The tests were made against 1,25-dihydroxyvitamin D₃ and are reported in Table 1.

TABLE 1

INTESTINAL CALCIUM TRANSPORT AND BONE CALCIUM MOBILIZING ACTIVITIES OF 26,27-DIMETHYLENE-1 α ,25-DIHYDROXYVITAMIN D ₂ AND 26,27-DIMETHYLENE-24-EPI-1 α ,25-DIHYDROXYVITAMIN D ₂			
Treatment	Doses (pmoles/day)	Intestinal Calcium Transport Serosal/Mucosal	Bone Calcium Mobilization (Serum Calcium) (mg/100 ml)
None	0	3.0 \pm 0.2	4.2 \pm 0.2
1,25-(OH) ₂ D ₃	130	8.5 \pm 0.9	5.7 \pm 0.3
Dimethylen-	130	5.2 \pm 0.4	4.4 \pm 0.1
1,25-(OH) ₂ D ₂	325	6.6 \pm 0.6	5.8 \pm 0.1
Dimethylen-24-epi-	130	6.3 \pm 0.3	4.4 \pm 0.1
1,25-(OH) ₂ D ₂	325	7.8 \pm 0.1	5.1 \pm 0.4

The results show that the dimethylene-1,25-dihydroxy-vitamin D₂ and the dimethylene-24-epi-1,25-dihydroxy-vitamin D₂ are both less active than 1,25-dihydroxy-vitamin D₃ in both the mobilization of calcium from bone and intestinal calcium transport. However, both of the 26,27-dimethylene-D₂ compounds have highly significant intestinal calcium transport activity. The amount of bone calcium mobilizing activity is considerably less than 1,25-dihydroxyvitamin D₃, and in the case of the 24-epi-compound, it is considerably less active in this regard. These compounds, therefore, by showing preferential activity on intestinal calcium transport and reduced calcium mobilizing activity in bone suggest that they disease where bone loss is a major issue, such as osteoporosis, osteomalacia and renal osteodystrophy.

Example 3 - Measurement of Differentiation in HL-60 Cells

The measurement of differentiation in HL-60 cells (human leukemia cells) was carried out according to

the general procedures described by DeLuca *et al.*, U. S. Patent 4,717,721. As shown in Table 2, degree of differentiation is assessed by a standard assay, namely, NBT reduction, and results are expressed as the percent of differentiated cells produced in response to treatment with various concentrations of vitamin D compounds.

TABLE 2

Differentiation Activity in HL-60 Cells in Culture		
Compound	% Cells Showing Differentiation	
	Concentration (molar)	NBT Reduction
1,25-(OH) ₂ D ₃	1 x 10 ⁻⁷	86 ± 3
	1 x 10 ⁻⁸	61 ± 3
	1 x 10 ⁻⁹	38 ± 4
26,27-Dimethylen- 1,25-(OH) ₂ D ₂	1 x 10 ⁻⁷	89 ± 3
	5 x 10 ⁻⁸	73 ± 4
	1 x 10 ⁻⁸	59 ± 4
	5 x 10 ⁻⁹	36 ± 4
	1 x 10 ⁻⁹	23 ± 2
	1 x 10 ⁻⁷	90 ± 3
26,27-Dimethylen- 24-epi-1,25- (OH) ₂ D ₂	5 x 10 ⁻⁸	77 ± 2
	1 x 10 ⁻⁸	63 ± 4
	5 x 10 ⁻⁹	44 ± 4
	1 x 10 ⁻⁹	21 ± 2

^aStandard error of the mean of 34 determinations.

The results of this assay is shown in Table 2. It is evident that the novel analogs (compounds 11a and 11b) are about equally as active as 1,25-(OH)₂D₃ itself in causing differentiation of HL-60 cells in culture.

The results shown in Figure 1 illustrate that these compounds when added to cultures of human HL-60 cells cause their differentiation into monocytes and show activity approximately equal to 1 α ,25-dihydroxyvitamin D₃. Figure 2 shows both 26,27-dimethylene- 1,25-di-hydroxyvitamin D₂ and its 24-epimer are at least equal in activity to 1,25-(OH)₂D₃ in binding to the 1,25-(OH)₂D pig intestinal nuclear receptor.

Because these compounds are at least as active as 1,25-(OH)₂D₃ in differentiation, receptor binding, and approximately equal in intestinal calcium transport activity but are very much less active in mobilizing bone calcium, they would appear to be ideal for treatment of diseases where bone formation is desired.

For treatment purposes, the novel compounds of this invention may be formulated for pharmaceutical applications as a solution in innocuous solvents, or as an emulsion, suspension or dispersion in suitable solvents or carriers, or as pills, tablets or capsules, together with solid carriers, according to conventional methods known in the art. Any such formulations may also contain other pharmaceutically-acceptable and non toxic excipients such as stabilizers, antioxidants, binders, coloring agents or emulsifying or taste-modifying agents.

The compounds may be administered orally, parenterally or transdermally. The compounds are advantageously administered by injection or by intravenous infusion of suitable sterile solutions, or in the form of liquid or solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications. Doses of from 0.5 μ g to 50 μ g per day of the compounds are appropriate for treatment purposes, such doses being adjusted according to the disease to be treated, its severity and the response of the subject as is well understood in the art. Since the new compounds exhibit specificity of action, each may be suitably administered alone, in situations where only calcium transport stimulation is desired, or together with graded doses of another active vitamin D compound — e.g. 1 α -hydroxyvitamin D₂ or D₃, or 1 α ,25-dihydroxyvitamin D₃— in situations where some degree of bone mineral mobilization (together with calcium transport stimulation) is found to be advantageous.

SCHEME I

5

10

15

20

25

30


35

40


45

50

55




SCHEME III




Claims

- 5 1. A compound having the formula:



where R^1 and R^2 may be hydrogen or methyl with the proviso that when R^1 is hydrogen R^2 cannot be hydrogen and when R^1 is methyl R^2 cannot be methyl.


- 25 2. 26,27-dimethylene-1 α ,25-dihydroxyvitamin D₂.
3. 26,27-dimethylene-24-*epi*-1 α ,25-dihydroxyvitamin D₂.
- 30 4. A compound having the formula:



where R^1 and R^2 are as defined in claim 1 for use in the treatment of a bone condition.

- 45 5. The use according to claim 4 where the condition is osteoporosis.
6. The use according to claim 4 where the condition is osteomalacia.
7. The use according to claim 4 where the condition is renal osteodystrophy.
- 50 8. The use according to any one of claims 4 to 7 where the compound is administered orally.
9. The use according to any one of claims 4 to 7 where the compound is administered parenterally.
- 55 10. The use according to any one of claims 4 to 7 where the compound is administered transdermally.
11. The use according to any one of claims 4 to 10 where the compound is administered in a dosage of from 0.5 μ g to 50 μ g per day.

12. A pharmaceutical composition containing at least one compound as claimed in claim 1, 2 or 3 together with a pharmaceutically acceptable excipient.
13. A composition according to claim 12 which contains 26,27-dimethylene-1 α ,25-dihydroxyvitamin D₂ in an amount from about 0.5 μ g to about 50 μ g.
14. A composition according to claim 12 which contains 26,27-dimethylene-24-epi-1 α ,25-dihydroxyvitamin D₂ in amount from about 0.5 μ g to about 50 μ g.
15. A compound having the formula:



where R¹ and R² may be hydrogen or methyl with the proviso that when R¹ is hydrogen R² cannot be hydrogen and when R¹ is methyl R² cannot be methyl, and R³, R⁴ and R⁵ may be, independently, hydrogen or a hydroxy-protecting group.

16. A compound according to claim 15 where R³ and R⁵ are both hydrogen and R⁴ is a hydroxy-protecting group.

FIG.1
HL-60 DIFFERENTIATION ACTIVITY




FIG. 2
COMPETITIVE BINDING

